Insulet Corporation shared new clinical data from its RADIANT study, a multinational randomized controlled trial. The study demonstrated that the Omnipod 5 Automated Insulin Delivery (AID) System provided clinically significant improvements in HbA1c compared with multiple daily injections (MDI) used with a continuous glucose monitor (CGM) for adults and children with Type 1 diabetes not previously meeting clinical targets.
Participants using Omnipod 5 improved their HbA1c by an average of 0.8%, resulting in a final HbA1c of 7.2%. For those starting with an HbA1c above 8.0%, the benefit was even greater, with a 1.0% improvement. Omnipod 5 users also spent an additional 5.4 hours per day with glucose levels in the target range (70-180mg/dL) and experienced significantly less time with high glucose levels, without increasing dangerously low glucose levels.
The RADIANT study is the first randomized controlled trial to evaluate the direct transition from MDI to an AID system in this population and the first to assess Omnipod 5 with an Abbott FreeStyle Libre 2 family sensor. These positive clinical trial results provide strong evidence for the efficacy and safety of the Omnipod 5 system, particularly for individuals transitioning directly from MDI therapy. This data supports broader adoption of Omnipod 5, especially in the large MDI user population, and strengthens Insulet's competitive position by demonstrating superior health outcomes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.